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http://dx.doi.org/10.1016/j.jmii.2013Background/Purpose: To investigate the clinical characteristics of Clostridium difficile infec-
tion (CDI) at a medical center in Taiwan.
Methods: Patients with CDI were identified from medical records at the National Taiwan Uni-
versity Hospital (Taipei, Taiwan). The following information was gathered and analyzed to
better understand the clinical manifestations of CDI: age; sex; underlying immunocompro-
mised conditions; laboratory data; in-hospital mortality; and previous use of drugs such as anti-
microbial agents, steroids, and antipeptic ulcer agents.
Results: During the years 2000e2010, 122 patients were identified as having CDI. This included
92 patients with nontoxigenic CDI (i.e., positive stool culture for C. difficile but negative re-
sults for toxins A and B) and 30 patients with toxigenic CDI (i.e., positive stool culture cultures
for C. difficile and positive results for toxins A and B). Of the 122 patients, 48 (39%) patients
were older than 65 years and most patients acquired the CDI while in the hospital. Active can-
cer was the most common reason for hospitalization, followed by diabetes mellitus, and end-
stage renal disease. More than 90% of the patients had received antibiotics before acquiringof Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of
tw (P.-R. Hsueh).
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492 C.-C. Lai et al.CDI. The results of fecal leukocyte examinations were positive in 33 (27%) patients. The overall
in-hospital mortality rate was 26.2%. There were no significant differences between patients
with nontoxigenic CDI and patients with toxigenic CDI.
Conclusion: Clostridium difficile infection can develop in healthcare facilities and in commu-
nity settings, especially in immunocompromised patients.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Clostridium difficile is a major causative pathogen of
antibiotic-associated diarrhea. In the past 20 years, there
has been a dramatic increase in the incidence and severity
of healthcare-associated C. difficile infection (CDI).1,2 In
the United States, the incidence of nosocomial C. difficile-
associated diarrhea increased from 31 per 100,000 people
in 1996 to 61 per 100,000 people in 2003. The incidence
rate, however, was significantly higher among patients with
an advanced age.3 In Canada, the mortality rate of
healthcare-associated CDI increased from 1.5% in 1997 to
5.7% in 2005.4 The results of studies from several countries
have shown a rising incidence of CDI.5e13 In Taiwan, testing
for C. difficile toxins was not a common practice in most
clinical microbiology laboratories, although cultures of
C. difficile for stool samples were usually obtained from
patients suspected of having CDI. The real situation of
toxigenic CDI in Taiwan consequently is unclear.14e17 The
objective of this study is to investigate the clinical char-
acteristics and outcomes of patients with CDI and to
compare the difference between patients with non-
toxigenic and toxigenic CDI.
Materials and methods
Setting
Patients with C. difficile infection were identified from
medical records at the National Taiwan University Hospital,
a 2500-bed medical center located in northern Taiwan. The
following information was gathered and analyzed to better
understand the clinical manifestations of CDI: age; sex;
underlying immunocompromised conditions such as a his-
tory of immunosuppressant drug use, diabetes mellitus,
liver cirrhosis, end-stage renal disease, malignancy, human
immunodeficiency virus (HIV) infection, and use of drugs
(e.g., immunosuppressants, steroid, antimicrobial agents,
steroid, and antipeptic ulcer agents) within 30 days of the
onset of symptoms; laboratory data obtained 2 days before
or 1 day after diagnosis; and in-hospital mortality.
Bacterial isolates and toxin detection
Liquid or semisolid stool samples were inoculated onto
cycloserine-cefoxitin-fructose agar (BBL Microbiology Sys-
tems, Cockeysville, MD, USA).18 After incubating the sam-
ple at 35C for 48 hours under anaerobic conditions,
C. difficile growth was identified by the Gram stainingresults (i.e., large Gram-positive rods), typical odor, and
biochemical characteristics, which were identified by the
Vitek Anaerobe Identification Card (bioMe´rieux, Inc., Bal-
timore, France). Before testing, the isolates of C. difficile
were frozen at e70C in brain-heart infusion broth (BBL
Microbiology Systems) and 15% glycerol. The production of
C. difficile toxin A or toxin B was detected by an enzyme-
linked fluorescent assay (bioMe´rieux, France) that was
performed directly on the stool.Definitions
Toxigenic CDI was diagnosed in patients who had clinical
symptoms of CDI (e.g., fever, diarrhea, abdominal
discomfort or distension, or ileus) and a stool sample that
tested positive for C. difficile and tested positive for toxin
A or toxin B.2 Nontoxigenic CDI was diagnosed in patients
who had clinical symptoms of nontoxigenic C. difficile and a
stool culture that was positive for C. difficile but negative
for toxin A or toxin B. The colonization of C. difficile was
defined in asymptomatic patients who had a stool culture
that was positive for C. difficile but negative for either
toxin. Healthcare-associated infection was diagnosed in
patients with the onset of CDI symptoms more than 48 hours
after their admission to a healthcare facility. Community-
acquired CDI was diagnosed in patients who had the onset
of CDI-associated symptoms while in the community or in
patients in whom symptoms appeared 48 hours or less after
their admission to a healthcare facilitydprovided that the
symptom onset was more than 30 days after the last
discharge from a healthcare facility.13 Antipeptic ulcer
drugs included proton pump inhibitors and histamine 2 (H2)
blockers. Active cancer was defined as a diagnosis of cancer
within 6 months before enrollment, any treatment for
cancer within the previous 6 months, or recurrent or met-
astatic cancer.19 Patients were considered to have an
immunocompromised condition if they had active cancer,
liver cirrhosis, autoimmune disorders, end-stage renal dis-
ease, HIV infection, or used immunosuppressants or
steroids.Statistical analysis
The Student t test was used to compare continuous vari-
ables between groups. The results are presented as the
mean  standard deviation (SD). The Chi-square test was
used to compare categorical variables between groups. All
statistical analyses were performed with the statistical
package software SPSS for Windows, version 12 (SPSS Inc.,
Clinical manifestations of C. difficile infection 493Chicago, Illinois, USA). A p value < 0.05 was considered
statistically significant.Results
Hospital setting and patients
During the years 2000e2010, 3024 of 26,424 (11.4%) stool
specimens tested positive for C. difficile (Fig. 1A).
Testing for C. difficile toxin at the National Taiwan Uni-
versity Hospital began in the year 2005, but this testing
was not reimbursed by the National Health InsuranceFigure 1. (A) The annual number of patients with stool culture t
annual number of patients with stool specimen testing p
C. difficile Z Clostridium difficile.system. Thus, tests were not routinely performed for
each patient with a suspected case of CDI. Of the 940
specimens that were examined for the presence of toxin
A or toxin B, only 50 (5.3%) stool specimens were positive
for the C. difficile toxin during the years 2005e2010; the
positive rate gradually decreased over time (Fig. 1B). We
identified 178 patients with stool cultures that were
positive for C. difficile and who were administered
concomitant toxin testing from 2005e2010. Among the
patients, 92 patients were diagnosed as having non-
toxigenic CDI, 30 patients were diagnosed as having
toxigenic CDI, and colonization of C. difficile was diag-
nosed in the remaining 56 patients.esting positive for C. difficile in the years 2000e2010. (B) The
ositive for C. difficile toxins in the years 2005e2010.
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C. difficile, nontoxigenic CDI, and toxigenic CDI
Table 1 shows the clinical characteristics of the 178 patients
with a positive stool culture for C. difficile. We found that
the patients with colonization of C. difficile were signifi-
cantly younger than patients with nontoxigenic CDI
(p Z 0.0274). Of the 122 patients with CDI (toxigenic and
nontoxigenic), 48 (39%) patients were older than 65 years
and 75 (84%) patients were men. Most patients had
healthcare-associated infection. Cancer was the most com-
mon underlying illness, followed by diabetes mellitus and
end-stage renal disease. More than 90% of patients had
received antibiotics prior to acquiring toxigenic or non-
toxigenic C. difficile infection. Cephalosporin was the most
common antibiotic used. More than one-half of the patients
who acquired CDI had received antipeptic ulcer drugs. Pro-
ton pump inhibitors were the most commonly prescribed
agents. The overall in-hospital mortality rate was 29.8%. To
investigate the differences between patients with non-
toxigenic and toxigenic CDI, we analyzed the clinical fea-
tures of each group of patients (Tables 1 and 2). There were
no significant differences between the two groups in age,Table 1 Clinical characteristics of 178 patients with positive st
Characteristic Colonization (n Z 56)
Age, mean  SD 38.38  32.27a
Age > 65 y 17 (30.35)
Male, n (%) 28 (50.00)
Healthcare-associated infection
Underlying disease
Active cancer 28 (50.00)
Diabetes mellitus 13 (23.21)
End-stage renal disease 1 (5.00)
Liver cirrhosis 2 (3.57)
Autoimmune disease 3 (5.36)
HIV infection 0 (0.00)
Receiving immunosuppressant 16 (28.57)
Receiving steroid 8 (14.29)
Laboratory examinations
White blood cell (cell/mL) 9655.31  10,139.56
Neutrophil counts 5771.70  5661.62
ANC < 500 (cell/mL) 4 (7.1)
Hemoglobin (g/dL) 10.37  1.75
AST (IU/L) 37.42  27.89
Albumin (mg/dL) 3.71  0.84
Creatinine (mg/dL) 1.09  1.39
CRP (mg/dL) 5.98  8.14
Positive stool pus cell 15 (26.79)
Antipeptic ulcer drug 30 (53.57)
Proton pump inhibitor 21 (37.50)
H2 blocker 12 (21.43)
In-hospital mortality 19 (33.93)
a Indicates a significant difference between patients with C. difficile
Data are presented as n (%) or mean  SD.
ANC Z absolute neutrophil count; AST Z aspartate aminotransferase
H2 Z histamine 2; SD Z standard deviation.sex, underlying diseases, laboratory findings, antimicrobial
use, antipeptic ulcer drug use, or in-hospital mortality.
Outcome analysis
Of the 30 patients with toxigenic CDI, 4 died in the hospital
(13.3%) and all had an underlying malignancy and
healthcare-associated CDI. Furthermore, we found a higher
frequency of active cancer among patients with mortality
than among surviving patients (p Z 0.003; Table 3).
Discussion
In this retrospective study, we found that the clinical
manifestation in patients with nontoxigenic CDI was similar
to the manifestation in patients with toxigenic CDI.
Furthermore, the in-hospital mortality rate did not differ
significantly between patients with nontoxigenic CDI and
patients with toxigenic CDI. However, because of the
limited number of patients in the present work, further
large scale studies are still needed to clarify this finding. In
the present study, healthcare-associated CDI unsurpris-
ingly comprised most cases of CDI, although more than 20%ool cultures for Clostridium difficile
Nontoxigenic C. difficile
infection (n Z 92)
Toxigenic C. difficile
infection (n Z 30)
52.51  40.21a 49.47  29.85
37 (40.21) 11 (36.67)
55 (59.19) 20 (66.67)
80 (86.96) 23 (76.67)
44 (47.83) 18 (60.00)
16 (17.39) 6 (20.00)
10 (10.87) 2 (6.67)
6 (6.52) 1 (3.33)
3 (3.26) 2 (6.67)
1 (1.09) 0 (0.00)
25 (27.17) 5 (16.67)
7 (7.61) 3 (10.00)
8969.01  7310.23 7962.59  5515.18
6461.48  6334.30 5321.66  4505.09
12 (13.04) 5 (16.67)
9.92  2.11 9.98  2.12
40.00  31.74 36.21  27.57
3.40  0.77 3.31  0.89
1.45  1.53 1.20  1.08
6.32  5.68 6.13  4.78
23 (25.00) 10 (33.33)
49 (53.26) 16 (53.33)
44 (47.82) 15 (50.00)
10 (10.86) 1 (3.33)
28 (30.43) 4 (13.33)
colonization and patients with nontoxigenic C. difficile infection.
; C. difficile Z Clostridium difficile; CRP Z C-reactive protein;
Table 2 The association between antibiotic exposure and Clostridium difficile infection
Characteristic Nontoxigenic C. difficile
infection (n Z 92)
Toxigenic C. difficile
infection (n Z 30)
p
Any 88 (95.65) 29 (96.67) 0.775
Penicillin drugs 53 (57.61) 13 (43.33) 0.249
Any cephalosporins 76 (82.61) 21 (70.00) 0.220
First generation 12 (13.04) 7 (23.33) 0.289
Second generation 11 (11.96) 4 (13.33) 0.899
Third generation 38 (41.30) 6 (20.00) 0.037
Fourth generation 45 (48.91) 15 (50.00) 0.915
Fluoroquinolones 37 (40.21) 13 (43.33) 0.930
Carbapenems 41 (44.57) 11 (36.67) 0.584
Glycopeptides 33 (35.86) 12 (40.00) 0.849
Aminoglycosides 13 (14.13) 3 (10.00) 0.787
Clindamycin 1 (1.09) 0 (0.00) 0.555
Antifungal agent 34 (36.96) 13 (43.33) 0.683
Data are presented as n (%).
C. difficile Z Clostridium difficile.
Clinical manifestations of C. difficile infection 495of cases of CDI were classified as a community-acquired
infection. In a recent population study conducted in the
United States, the authors reported that community-
acquired CDI accounted for 41% of 385 confirmed cases of
CDI and that the incidence increased between 1991 and
2005.20 The occurrence of community-acquired CDI was
less in this study than in the United States study20; how-
ever, more epidemiologic studies should be performed to
establish the clinical impact of community-acquired CDI.
Of the 122 patients with CDI (toxigenic and non-
toxigenic), 100 (82%) patients were immunocompromised.
However, we could not explore the association between CDI
and the underlying immunocompromised conditions
because of the small number of patients. In addition, more
than one-third of the patients with CDI were of advanced
age. A similar finding was reported by Viswanathan et al.21
In this study, we found that more than 90% of patients
with CDI had a previous history of antibiotic usage.
Extended-spectrum cephalosporins, including third and
fourth generation cephalosporins, were the most commonTable 3 Risk factors associated with in-hospital mortality in pa
Variable Survival (n Z 26
Age > 65 y 10 (38.46)
Female sex 8 (30.79)
Healthcare-associated infection 21 (80.77)
Community-acquired infection 5 (19.23)
Active cancer 14 (53.85)
Diabetes mellitus 6 (23.08)
Receiving immunosuppressant
treatment
4 (15.38)
Use of antipeptic ulcer drug 15 (57.69)
Treatment
Metronidazole 21 (80.77)
Vancomycin 4 (15.38)
a Indicates a significant difference.
Data are presented as n (%).
C. difficile Z Clostridium difficile.antecedent antibiotics. We also noted that the use of third
generation cephalosporin is higher in patients with non-
toxigenic CDI than in patients with toxigenic CDI. We also
found that more than one-third of patients with CDI had
received antifungal agents. The association between the
previous use of antifungal agents and the development of
CDI requires further study.
Fecal leukocyte examination is routinely performed as
an initial diagnostic tool for hospitalized patients with
diarrhea. We found that the test was positive in only 27% of
patients with CDI. This finding is consistent with previous
studies that showed that the sensitivity of fecal leukocyte
testing is as low as 22.7%.16,22 Therefore, this test is not a
good predictor of CDI.
The overall in-hospital mortality rate in this study was
approximately 26%. The mortality of toxigenic CDI was
associated with active cancer. In a study of 86 hospitalized
patients with CDI in southern Taiwan, the crude in-hospital
mortality rate was 37%.16 By contrast, the mortality rate was
only 5% in a recent study of 485 cases of laboratory-confirmedtients with toxigenic Clostridium difficile infection
) Mortality (n Z 4) p
1 (25.0) 0.9703
2 (50.0) 0.8501
4 (100.0) 0.8078
0 (0.0) 0.8078
4 (100.0) 0.0031a
0 (0.0) 0.6870
1 (25.0) 0.8103
1 (25.0) 0.4954
4 (100.0) 0.8102
1 (25.0) 0.8103
496 C.-C. Lai et al.CDI.23 The variation in mortality in these studies may be
because different study populations and study designs were
used. In the present study, most patients with CDI had un-
derlying immunocompromised conditions.
We also did not find that acid suppression was associated
with an increased risk of death, which contrasts with the
results by Morrison et al23 (odds ratio, 4.74; 95% confidence
interval, 1.57e14.37). Further large-scale epidemiological
studies are needed to clarify the relationship between the
use of acid suppressing agents and the outcome of CDI.
There were several limitations in this study. In this
retrospective analysis, a relatively limited number of CDI
cases were identified. Therefore, most findings may not
reach a significant difference. In addition, only patients
with a positive culture and who received toxin examina-
tions were enrolled.
In conclusion, CDI can developdespecially in immuno-
compromised patientsdin community settings and in
healthcare facility settings. Physicians should keep this
clinical entity in consideration, especially in patients with
risk factors. We found that the role of fecal leukocyte
testing is limited for CDI.
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